Clinical trials and real-world data consistently show significant weight loss from treatment with Ozempic, Semaglutide and Tirzepatide: Unfortunately, weight regain is a well-documented phenomenon after discontinuation of treatment: SURMOUNT 4 trial- Weight regain after stopping Tirzepatide after 36 weeks versus continuation of treatment Beyond weight regain, the discontinuation of GLP-1 agonists may reverse cardiometabolic benefits: Ongoing trials (e.g., SELECT and SURPASS-CVOT) aim to clarify whether continued use is necessary for sustained cardiovascular risk reduction
Before recommending a compounded Semaglutide structure, well discuss all available treatment options with you, assess why the brand-name medication may not be suitable, and determine if a compounded version is clinically appropriate
Similarly, liraglutide dosing depends on the form you're taking
Contaminated GHK-Cu shows additional signs: yellow or brown discolouration, a distinct odour (often musty or sour), and sometimes a visible pellicle (film) on the surface
This means there are no generic versions on the market yet